Table 3 Logistic regression univariate and multivariate analyses of factors predicting SARS-CoV-2 breakthrough infection after full vaccination
Characteristics | SARS-CoV-2 infection | p value | SARS-CoV-2 infection | p value |
|---|---|---|---|---|
Univariate OR (95% CI) | Multivariate OR (95% CI) | |||
Prior COVID-19 | 0.2 (0.02–1.2) | 0.1 | ns | |
Type of vaccine | ||||
Moderna mRNA-1273 | 1 | |||
Pfizer-BionTech BNT162b2 | 0.6 (0.14–2.6) | 0.5 | ||
Adenoviral vector-based | 0.75 (0.16–3.5) | 0.7 | ||
Age (years) | ||||
18–40 years | 1 | |||
41–60 years | 0.8 (0.32–2.1) | 0.67 | ||
61–70 years | 0.37 (0.12–1.18) | 0.09 | ns | |
> 71 years | 0.49 (0.16–1.44) | 0.19 | ||
Male sex | 1.6 (0.8–3.2) | 0.166 | ||
Baseline disease | ||||
ALL | 1 | |||
AML | 1.3 (0.14–11.2) | 0.8 | ||
MDS | 1.47 (0.16–33) | 0.7 | ||
B-cell NHL | 0.76 (0.08–6.6) | 0.8 | ||
T cell NHL | 3.8 (0.38–38.4) | 0.25 | ||
Plasma cell disorders | 0.97 (0.11–8.5) | 0.9 | ||
CLL | 1.16 (0.12–10.7) | 0.9 | ||
HD | 2.78 (0.32–23.8) | 0.35 | ||
cMPN | 0.65 (0.05–7.4) | 0.7 | ||
Aplastic anemia | 0.000 | 0.99 | ||
Non-malignant disorders | 2.6 (0.15–44.7) | 0.5 | ||
Status disease at vaccination | ||||
Complete remission | 1 | |||
Partial remission | 1.47 (0.58–3.7) | 0.4 | ||
Active disease | 0.92 (0.45–2.06) | 0.9 | ||
Time from last treatment to COVID-19 vaccine | ||||
Untreated | 1 | |||
Under treatment | 0.47 (0.17–1.26) | 0.13 | ||
> 6 months to 1 year | 1.35 (0.41–4.39) | 0.6 | ||
≥ 1 year | 0.58 (0.23–1.45) | 0.24 | ||
Cell therapy | ||||
Yes | 0.58 (0.3–1.1) | 0.1 | ns | |
No | 1 | |||
Allo-HSCT | 1.6 (0.82–3.4) | 0.15 | ||
ASCT | 2.19 (0.8–5.98) | 0.12 | ||
CAR-T | 0.00 | 0.99 | ||
Corticosteroids at vaccination | 1.2 (0.56–2.7) | 0.59 | ||
Daratumumab | 0.8 (0.1–6) | 0.83 | ||
Venetoclax | 0.00 | 0.99 | ||
Anti-CD-20 moAb | 0.57 (0.2–1.6) | 0.29 | ||
Bruton’s TKI therapy | 1.9 (0.57–6.4) | 0.29 | ||
TKI therapy | 0.95 (0.12–7) | 0.9 | ||
Lenalidomide | 0.6 (0.14–2.5) | 0.48 | ||
Ruxolitinib therapy | 0.00 | 0.99 | ||
SCoV2-R-A negative at 3–6 weeks after 2 doses | 2.5 (1.3–4.9) | 0.007 | 2.35 (1.2–4.6) | 0.012 |
Lymphocyte count < 0.5 × 109/L | 0.75 (0.09–5.4) | 0.75 | ||
Lymphocyte count < 1.0 × 109/L | 1.5 (0.7–3.3) | 0.27 | ||